{"organizations": [], "uuid": "4eeea28115917b275a28df1cde9e2b0e4fcc63e1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-avexis-announces-expanded-clinical/brief-avexis-announces-expanded-clinical-development-program-for-avxs-101-in-spinal-muscular-atrophy-idUSFWN1PB0LZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Avexis Announces Expanded Clinical Development Program For AVXS-101 In Spinal Muscular Atrophy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-16T14:53:00.000+02:00", "replies_count": 0, "uuid": "4eeea28115917b275a28df1cde9e2b0e4fcc63e1"}, "author": "", "url": "https://www.reuters.com/article/brief-avexis-announces-expanded-clinical/brief-avexis-announces-expanded-clinical-development-program-for-avxs-101-in-spinal-muscular-atrophy-idUSFWN1PB0LZ", "ord_in_thread": 0, "title": "BRIEF-Avexis Announces Expanded Clinical Development Program For AVXS-101 In Spinal Muscular Atrophy", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "spinal muscular atrophy reuters", "sentiment": "none"}, {"name": "avexis inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 53 PM / Updated 9 minutes ago BRIEF-Avexis Announces Expanded Clinical Development Program For AVXS-101 In Spinal Muscular Atrophy Reuters Staff \nJan 16 (Reuters) - Avexis Inc: \n* AVEXIS ANNOUNCES EXPANDED CLINICAL DEVELOPMENT PROGRAM FOR AVXS-101 IN SPINAL MUSCULAR ATROPHY \n* AVEXIS - TO EXPAND STUDY OF AVXS-101 INTO ADDITIONAL SMA POPULATIONS INCLUDING PRE-SYMPTOMATIC, OLDER PEDIATRIC TYPE 2 AND TYPE 3 SMA PATIENTS \n* AVEXIS INC - ‍PLANS TO INITIATE THREE STUDIES TO FURTHER EVALUATE AVXS-101, INCLUDING IN NEW SMA PATIENT POPULATIONS​ \n* AVEXIS INC - ‍EXPECTS TO INITIATE PIVOTAL TRIAL OF AVXS-101 IN SMA TYPE 1 IN EUROPE​ IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-16T14:53:00.000+02:00", "crawled": "2018-01-16T15:12:45.042+02:00", "highlightTitle": ""}